Transaction DateRecipientSharesTypePriceValue
2nd December 2020Advisors Llc Orbimed300,000Open or private purchase$20.00$6,000,000.00
2nd December 2020Advisors Llc Orbimed450,000Open or private purchase$20.00$9,000,000.00
17th November 2020Advisors Llc Orbimed434,008Exercise of in-the-money or at-the-money derivatives securities (usually options)$0.01$4,340.08
17th November 2020Advisors Llc Orbimed765,992Exercise of in-the-money or at-the-money derivatives securities (usually options)$0.01$7,659.92
17th November 2020Advisors Llc Orbimed868,016Exercise of in-the-money or at-the-money derivatives securities (usually options)$0.01$8,680.16
17th November 2020Advisors Llc Orbimed1,531,984Exercise of in-the-money or at-the-money derivatives securities (usually options)$0.01$15,319.84
17th November 2020Advisors Llc Orbimed434,008Exercise of in-the-money or at-the-money derivatives securities (usually options)$0.01$4,340.08
17th November 2020Advisors Llc Orbimed765,992Exercise of in-the-money or at-the-money derivatives securities (usually options)$0.01$7,659.92
9th October 2020Chau Quang Khuong91Grant/award etc.$130.00$11,830.00
2nd October 2020Advisors Llc Orbimed200,000Open or private purchase$25.00$5,000,000.00
Next Cure
Next Cure logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.


NextCure, Inc. is a clinical-stage biopharmaceutical company. It is developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function.


Ticker: NXTC
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1661059
Employees: 44
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals